Subcutaneous formulation off to an encouraging start; R&D pipeline progressing well
13/08/20 -"Despite being slightly impacted by COVID-19 in Q2, Darzalex continued to gain share in the multiple myeloma market. Given the encouraging launch of the subcutaneous formulation, we anticipate a ..."
Pages
49
Language
English
Published on
13/08/20
You may also be interested by these reports :
05/08/26
The Q2 results exceeded expectations, aided by sustained strong uptake for the Wegovy pill (obesity). Consequently, the management upgraded its ...
04/08/26
BioNTech reported a disappointing quarter, with sales significantly below forecasts and operating losses exceeding expectations. Weaker Covid-19 ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...
03/08/26
Astra’s media-reported merger/acquisition talks with Bristol Myers Squibb (BMS) entail worries for Astra’s shareholders – considerable overlapping ...